Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Testicular hypofunction and multiple sclerosis risk: a record-linkage study.
From Bugs to Brains: the gut microbiome in neurological health
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™ (peginterferon beta-1a)
Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate.
Foxp3(+) Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.
Biomarkers for Brain Disorders: Challenges and Opportunities
Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease.
Primary infection with the Epstein-Barr virus and risk of multiple sclerosis.
Product Portfolio, Meda
Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone.
Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs.
Bioengineered cell culture systems of central nervous system injury and disease.
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.
Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis.
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.
Two endogenous retroviral loci appear to contribute to Multiple Sclerosis.
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
Epigenetic modifications of Dexras 1 along the nNOS pathway in an animal model of multiple sclerosis.
Clinical Reasoning: Left hemiparesis, ataxia, and optic neuritis in a child previously treated for pineoblastoma.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Pages